drugset / Trial / NCT03230825

Oral Contraceptive Pills Versus Expectant Management for Retained Pregnancy Products

NCT03230825

Unknown 100 enrolled Meir Medical Center
RandomizedParallel-groupSingle-blindTreatment

Summary

We speculate that the use of combined oral contraceptives may be a possible solution to promote the management of retained pregnancy products versus expectant management. By withdrawing the pill, the endometrium is expected to shed in a synchronized fashion (estrogen and progestin withdrawal bleeding and may also shed the retained products of conception and avoid a surgical procedure with its related potential complications.

Timeline

Start
2017-09
Primary completion
2018-09
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Gestodene Small molecule 0.075 mg Oral
Subject ethinyl estradiol Small molecule 0.02 mg Oral

Indications

No indication recorded.